Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trialThierry Conroy, Jean‐Baptiste Bachet, Jean-François Bosset et al.|The Lancet Oncology|2021Cited by 1.3k
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Jong‐Mu Sun, Jianhua Chen et al.|Journal of Clinical Oncology|2022Cited by 306
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H. Strickler, Andrea Cercek, Salvatore Siena et al.|The Lancet Oncology|2023Cited by 244
Predictors of responses to immune checkpoint blockade in advanced melanomaNicolas Jacquelot, Laurence Zitvogel, María P. Roberti et al.|Nature Communications|2017Cited by 201
Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trialThierry Conroy, Christophe Borg, Florence Castan et al.|Annals of Oncology|2024Cited by 187